EP3679053A4 - Hochaffines cxcr4-selektives bindungskonjugat und verfahren zur verwendung davon - Google Patents
Hochaffines cxcr4-selektives bindungskonjugat und verfahren zur verwendung davon Download PDFInfo
- Publication number
- EP3679053A4 EP3679053A4 EP18852912.7A EP18852912A EP3679053A4 EP 3679053 A4 EP3679053 A4 EP 3679053A4 EP 18852912 A EP18852912 A EP 18852912A EP 3679053 A4 EP3679053 A4 EP 3679053A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- same
- high affinity
- selective binding
- binding conjugate
- affinity cxcr4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762554354P | 2017-09-05 | 2017-09-05 | |
PCT/US2018/018530 WO2019050564A1 (en) | 2017-09-05 | 2018-02-17 | CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3679053A1 EP3679053A1 (de) | 2020-07-15 |
EP3679053A4 true EP3679053A4 (de) | 2021-10-27 |
Family
ID=65635072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18852912.7A Pending EP3679053A4 (de) | 2017-09-05 | 2018-02-17 | Hochaffines cxcr4-selektives bindungskonjugat und verfahren zur verwendung davon |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3679053A4 (de) |
JP (1) | JP2020532496A (de) |
KR (2) | KR20200043970A (de) |
CN (1) | CN111183146A (de) |
CA (1) | CA3065086A1 (de) |
WO (1) | WO2019050564A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11123437B2 (en) | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
JP2021165234A (ja) * | 2018-07-03 | 2021-10-14 | 富士フイルム富山化学株式会社 | Cxcr4結合性化合物もしくはその塩またはそれらと金属との錯体 |
EP3956346A4 (de) * | 2019-04-18 | 2023-01-18 | Provincial Health Services Authority | Neuartige radiomarkierte gegen cxcr4 gerichtete verbindungen zur diagnose und therapie |
WO2021150258A1 (en) * | 2020-01-26 | 2021-07-29 | Mainline Biosciences Llc | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same |
JP2024518287A (ja) * | 2022-02-11 | 2024-05-01 | シーバイオメックス カンパニー リミテッド | 炭酸脱水素酵素ixを標的にするペプチドリガンド、これを含むペプチド構造体及びその用途 |
CN114832113B (zh) * | 2022-03-22 | 2023-06-20 | 重庆医科大学 | 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用 |
WO2023201435A1 (en) * | 2022-04-20 | 2023-10-26 | Provincial Health Services Authority | Cxcr4-targeting compounds, and methods of making and using the same |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007096662A2 (en) * | 2006-02-27 | 2007-08-30 | Technische Universität München | Cancer imaging and treatment |
WO2008150689A1 (en) * | 2007-05-30 | 2008-12-11 | Eli Lilly And Company | Cyclic peptide cxcr4 antagonists |
CN102626522A (zh) * | 2012-04-12 | 2012-08-08 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
US20130079292A1 (en) * | 2010-01-26 | 2013-03-28 | Consiglio Nazionale Delle Ricerche | Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses |
US20150050351A1 (en) * | 2013-01-02 | 2015-02-19 | Lucia Irene Gonzalez | Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis. |
US20150218219A1 (en) * | 2012-06-06 | 2015-08-06 | Polyphor Ag | Beta-hairpin peptidomimetics |
WO2015185162A1 (en) * | 2014-06-06 | 2015-12-10 | Technische Universität München | Modified cyclopentapeptides and uses thereof |
-
2018
- 2018-02-17 JP JP2020504380A patent/JP2020532496A/ja active Pending
- 2018-02-17 EP EP18852912.7A patent/EP3679053A4/de active Pending
- 2018-02-17 KR KR1020207000227A patent/KR20200043970A/ko not_active IP Right Cessation
- 2018-02-17 CN CN201880049498.7A patent/CN111183146A/zh active Pending
- 2018-02-17 WO PCT/US2018/018530 patent/WO2019050564A1/en unknown
- 2018-02-17 KR KR1020237034343A patent/KR20230145543A/ko active Search and Examination
- 2018-02-17 CA CA3065086A patent/CA3065086A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007096662A2 (en) * | 2006-02-27 | 2007-08-30 | Technische Universität München | Cancer imaging and treatment |
WO2008150689A1 (en) * | 2007-05-30 | 2008-12-11 | Eli Lilly And Company | Cyclic peptide cxcr4 antagonists |
US20130079292A1 (en) * | 2010-01-26 | 2013-03-28 | Consiglio Nazionale Delle Ricerche | Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses |
CN102626522A (zh) * | 2012-04-12 | 2012-08-08 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
US20150218219A1 (en) * | 2012-06-06 | 2015-08-06 | Polyphor Ag | Beta-hairpin peptidomimetics |
US20150050351A1 (en) * | 2013-01-02 | 2015-02-19 | Lucia Irene Gonzalez | Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis. |
WO2015185162A1 (en) * | 2014-06-06 | 2015-12-10 | Technische Universität München | Modified cyclopentapeptides and uses thereof |
Non-Patent Citations (3)
Title |
---|
PENG SHENG-BIN ET AL: "Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 2, 1 February 2015 (2015-02-01), pages 480 - 490, XP002771606, ISSN: 1538-8514, DOI: 10.1158/1535-7163.MCT-14-0850 * |
YAN WANG ET AL: "Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery", CURRENT PHARMACOLOGY REPORTS, vol. 2, no. 1, 4 January 2016 (2016-01-04), pages 1 - 10, XP055747815, DOI: 10.1007/s40495-015-0044-8 * |
YASUSHI YOSHIKAWA ET AL: "Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4FC131 interactions", BIORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 22, no. 6, 31 January 2012 (2012-01-31), pages 2146 - 2150, XP028402827, ISSN: 0960-894X, [retrieved on 20120208], DOI: 10.1016/J.BMCL.2012.01.134 * |
Also Published As
Publication number | Publication date |
---|---|
EP3679053A1 (de) | 2020-07-15 |
CA3065086A1 (en) | 2019-03-14 |
CN111183146A (zh) | 2020-05-19 |
WO2019050564A1 (en) | 2019-03-14 |
KR20200043970A (ko) | 2020-04-28 |
JP2020532496A (ja) | 2020-11-12 |
KR20230145543A (ko) | 2023-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3679053A4 (de) | Hochaffines cxcr4-selektives bindungskonjugat und verfahren zur verwendung davon | |
EP3725798A4 (de) | Bioaktives konjugat, verfahren zu seiner herstellung und seine verwendung | |
EP3732920A4 (de) | Technologie, vorrichtungen und verfahren im zusammenhang mit einer übergabe | |
EP3694633A4 (de) | Mikroporöse membranen, verfahren zu ihrer herstellung und verwendung | |
EP3694181A4 (de) | Sitzungsherstellungsverfahren, -vorrichtung und -system | |
EP3694257A4 (de) | Verfahren, vorrichtung und system zur sitzungsherstellung | |
EP3733715A4 (de) | Triabody, verfahren zu seiner herstellung und seine verwendung | |
EP3621641A4 (de) | Anti-cd3-bindende domänen und antikörper, die diese enthalten, sowie verfahren zu ihrer herstellung und verwendung | |
EP3615612A4 (de) | Thermoplastische zusammensetzungen, verfahren, vorrichtung und verwendungen | |
EP3720235A4 (de) | Sitzungsherstellungsverfahren, -vorrichtung und -system | |
EP3648506A4 (de) | Verfahren, vorrichtung und system zur aktivierung einer sitzung | |
EP3689893A4 (de) | Immunglobulin-bindendes protein und affinitätsträger damit | |
EP3704227A4 (de) | Zusammensetzung und verfahren | |
EP3632907A4 (de) | N-(azaaryl) cyclolactam-1-carboxamid-derivat, herstellungsverfahren dafür und verwendung davon | |
EP3687540A4 (de) | Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon | |
EP3617218A4 (de) | Dihydroartemisinin-steroid-konjugat und herstellungsverfahren und verwendung davon | |
EP3594312A4 (de) | Zusammensetzung, verfahren zur herstellung davon und verwendung davon | |
EP3627322A4 (de) | Anwendungsinteraktionsverfahren, interaktionsverfahren und -vorrichtung | |
EP3720203A4 (de) | Sitzungsaufbauverfahren, -vorrichtung und -system | |
EP3398958A4 (de) | Polyamiosäure, protein-polyaminosäure-konjugat und herstellungsverfahren dafür | |
EP3589670A4 (de) | Elastomer, verfahren zur herstellung davon und verwendung davon | |
EP3689894A4 (de) | Immunglobulin-bindendes protein und affinitätsträger damit | |
EP3643095A4 (de) | Verfahren zur durchführung eines rlau verfahrens und vorrichtung damit | |
EP3699179A4 (de) | Pyrazolhaltiges tricyclisches derivat, herstellungsverfahren dafür und verwendung davon | |
EP4061236C0 (de) | Nadelführungssysteme, komponenten und verfahren dafür |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191126 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 7/06 20060101AFI20210621BHEP Ipc: C07K 7/50 20060101ALI20210621BHEP Ipc: C07K 5/12 20060101ALI20210621BHEP Ipc: A61K 38/00 20060101ALI20210621BHEP Ipc: A61K 49/00 20060101ALI20210621BHEP Ipc: C07K 14/705 20060101ALI20210621BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210927 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/705 20060101ALI20210921BHEP Ipc: A61K 49/00 20060101ALI20210921BHEP Ipc: A61K 38/00 20060101ALI20210921BHEP Ipc: C07K 5/12 20060101ALI20210921BHEP Ipc: C07K 7/50 20060101ALI20210921BHEP Ipc: C07K 7/06 20060101AFI20210921BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240314 |